Opus Genetics (IRD)
Opus Genetics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
13.3M
Short interest
settlement 2026-10-15
7.4
Days to cover
+1.4 days vs prior
65.0%
Short share of volume
2026-11-02
99
Fails to deliver
settlement 2026-10-14
Wed 11 Nov
Next earnings
estimated date
-$3.1M
Insider flow, 90 days
0 buys, 7 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in IRD is 13,337,904 shares, up 759,132 shares over the last month. Over the last 48 readings it ranged from 54,164 shares (29 August 2025) to 13,337,904 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 1.8M shares a day that is 7.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/ird" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 13,337,904 | +2.5% | 1,798,991 | 7.41 |
| 2026-09-30 | 13,013,222 | +3.5% | 2,150,972 | 6.05 |
| 2026-09-15 | 12,578,772 | +15.3% | 8,352,775 | 1.51 |
| 2026-08-31 | 10,912,085 | -3.0% | 878,186 | 12.43 |
| 2026-08-14 | 11,248,349 | +3.7% | 733,903 | 15.33 |
| 2026-07-31 | 10,848,529 | +5.7% | 908,931 | 11.94 |
| 2026-07-15 | 10,265,963 | +24.8% | 820,063 | 12.52 |
| 2026-06-30 | 8,228,353 | +43.4% | 1,568,617 | 5.25 |
| 2026-06-15 | 5,737,860 | +46.5% | 806,434 | 7.12 |
| 2026-05-29 | 3,917,871 | +26.0% | 807,581 | 4.85 |
| 2026-05-15 | 3,109,049 | +55.5% | 971,585 | 3.20 |
| 2026-04-30 | 1,999,457 | +10.7% | 927,511 | 2.16 |
| 2026-04-15 | 1,807,078 | -2.1% | 658,145 | 2.75 |
| 2026-03-31 | 1,846,316 | -8.3% | 670,317 | 2.75 |
| 2026-03-13 | 2,014,121 | +81.3% | 1,322,364 | 1.52 |
| 2026-02-27 | 1,110,696 | +17.9% | 888,480 | 1.25 |
| 2026-02-13 | 942,054 | +41.8% | 1,305,670 | 1.00 |
| 2026-01-30 | 664,201 | -30.6% | 924,259 | 1.00 |
| 2026-01-15 | 957,806 | +31.5% | 463,062 | 2.07 |
| 2025-12-31 | 728,362 | +14.5% | 294,160 | 2.48 |
| 2025-12-15 | 635,920 | +9.3% | 747,016 | 1.00 |
| 2025-11-28 | 581,546 | +50.5% | 371,780 | 1.56 |
| 2025-11-14 | 386,397 | -22.6% | 601,894 | 1.00 |
| 2025-10-31 | 499,215 | +61.6% | 478,399 | 1.04 |
| 2025-10-15 | 308,958 | +145.8% | 501,527 | 1.00 |
| 2025-09-30 | 125,683 | +39.5% | 436,975 | 1.00 |
| 2025-09-15 | 90,128 | +66.4% | 292,503 | 1.00 |
| 2025-08-29 | 54,164 | -69.2% | 149,813 | 1.00 |
| 2025-08-15 | 175,927 | -31.1% | 219,927 | 1.00 |
| 2025-07-31 | 255,248 | -48.5% | 215,229 | 1.19 |
| 2025-07-15 | 495,953 | -52.2% | 268,427 | 1.85 |
| 2025-06-30 | 1,037,558 | +111.9% | 1,221,339 | 1.00 |
| 2025-06-13 | 489,684 | +216.5% | 4,569,514 | 1.00 |
| 2025-05-30 | 154,728 | -33.8% | 127,071 | 1.22 |
| 2025-05-15 | 233,621 | +131.3% | 162,974 | 1.43 |
| 2025-04-30 | 101,027 | -20.4% | 176,297 | 1.00 |
| 2025-04-15 | 126,990 | -6.7% | 239,938 | 1.00 |
| 2025-03-31 | 136,163 | -80.1% | 420,744 | 1.00 |
| 2025-03-14 | 685,446 | -2.5% | 108,709 | 6.31 |
| 2025-02-28 | 703,397 | +4.5% | 150,962 | 4.66 |
| 2025-02-14 | 672,994 | +8.4% | 180,902 | 3.72 |
| 2025-01-31 | 620,624 | -6.7% | 116,659 | 5.32 |
| 2025-01-15 | 664,850 | -16.4% | 235,783 | 2.82 |
| 2024-12-31 | 795,731 | -4.7% | 376,970 | 2.11 |
| 2024-12-13 | 835,092 | -5.0% | 191,416 | 4.36 |
| 2024-11-29 | 879,038 | +28.3% | 231,893 | 3.79 |
| 2024-11-15 | 685,011 | -26.9% | 170,956 | 4.01 |
| 2024-10-31 | 937,096 | +0.8% | 181,063 | 5.18 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of IRD volume is 65.0%, up 11.9 points over the last five sessions. Over the last 30 readings it ranged from 29.1% (6 October 2026) to 82.8% (29 September 2026). The latest reading is 7.7 points above the 30-session average of 57.3%, on 356K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 231K | 356K | 65.0% | 1,000 |
| 2026-10-30 | 224K | 371K | 60.2% | 1,071 |
| 2026-10-29 | 111K | 211K | 52.6% | 5 |
| 2026-10-28 | 184K | 324K | 57.0% | 0 |
| 2026-10-27 | 155K | 405K | 38.2% | 0 |
| 2026-10-26 | 319K | 602K | 53.0% | 0 |
| 2026-10-23 | 283K | 452K | 62.6% | 13,571 |
| 2026-10-22 | 210K | 356K | 58.9% | 38 |
| 2026-10-21 | 400K | 564K | 71.0% | 0 |
| 2026-10-20 | 315K | 516K | 61.2% | 0 |
| 2026-10-19 | 299K | 566K | 52.8% | 0 |
| 2026-10-16 | 886K | 1.2M | 72.4% | 3,259 |
| 2026-10-15 | 544K | 876K | 62.1% | 1,934 |
| 2026-10-14 | 295K | 516K | 57.2% | 0 |
| 2026-10-13 | 327K | 555K | 58.8% | 74 |
| 2026-10-12 | 320K | 493K | 64.9% | 0 |
| 2026-10-09 | 304K | 511K | 59.4% | 767 |
| 2026-10-08 | 268K | 486K | 55.2% | 137 |
| 2026-10-07 | 429K | 686K | 62.6% | 124 |
| 2026-10-06 | 346K | 1.2M | 29.1% | 883 |
| 2026-10-05 | 452K | 1.2M | 38.2% | 1,400 |
| 2026-10-02 | 505K | 780K | 64.8% | 2,054 |
| 2026-10-01 | 299K | 742K | 40.3% | 587 |
| 2026-09-30 | 448K | 1.3M | 34.0% | 122 |
| 2026-09-29 | 463K | 559K | 82.8% | 586 |
| 2026-09-28 | 328K | 537K | 61.1% | 772 |
| 2026-09-25 | 330K | 484K | 68.2% | 20 |
| 2026-09-24 | 416K | 896K | 46.4% | 0 |
| 2026-09-23 | 1.2M | 1.7M | 70.7% | 3,654 |
| 2026-09-22 | 351K | 606K | 58.0% | 7,911 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in IRD is 99 shares, unchanged over the last settlement date. Over the last 30 readings it ranged from 15 shares (31 August 2026) to 499,009 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 99 | $4.24 | $420 |
| 2026-10-13 | 99 | $4.64 | $459 |
| 2026-09-30 | 4,650 | $4.96 | $23K |
| 2026-09-28 | 3,515 | $4.76 | $17K |
| 2026-09-24 | 4,002 | $4.83 | $19K |
| 2026-09-21 | 1,500 | $5.18 | $8K |
| 2026-09-10 | 20,234 | $5.73 | $116K |
| 2026-09-03 | 406,888 | $4.45 | $1.8M |
| 2026-09-02 | 10,039 | $3.83 | $38K |
| 2026-09-01 | 1,226 | $3.62 | $4K |
| 2026-08-31 | 15 | $3.69 | $55 |
| 2026-08-25 | 15,073 | $4.03 | $61K |
| 2026-08-24 | 35,125 | $4.05 | $142K |
| 2026-08-18 | 1,247 | $3.65 | $5K |
| 2026-08-12 | 8,949 | $3.88 | $35K |
| 2026-08-05 | 1,130 | $3.71 | $4K |
| 2026-07-30 | 32,456 | $3.47 | $113K |
| 2026-07-29 | 4,632 | $3.41 | $16K |
| 2026-07-24 | 35,893 | $2.92 | $105K |
| 2026-07-23 | 883 | $3.05 | $3K |
| 2026-07-17 | 55 | $3.28 | $180 |
| 2026-07-16 | 1,154 | $3.48 | $4K |
| 2026-07-09 | 100 | $4.10 | $410 |
| 2026-07-08 | 52,492 | $4.05 | $213K |
| 2026-07-07 | 9,801 | $4.07 | $40K |
| 2026-07-06 | 13,703 | $4.23 | $58K |
| 2026-06-30 | 175,483 | $4.06 | $712K |
| 2026-06-29 | 499,009 | $4.00 | $2.0M |
| 2026-06-26 | 1,717 | $3.72 | $6K |
| 2026-06-25 | 27,924 | $3.71 | $104K |
Insider trades
SEC Form 4, newest first. JSONInsiders at IRD reported 7 open-market sells worth $3.1M in the last 90 days and no open-market buys. Latest filing: YERXA BENJAMIN R (President) on 2026-10-23.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | YERXA BENJAMIN R | President | Sell | 26K | $3.53 | $90K | 671K |
| 2026-10-23 | YERXA BENJAMIN R | President | Sell | 8K | $3.55 | $27K | 696K |
| 2026-10-23 | Magrath George | Chief Executive Officer | Sell | 10K | $3.58 | $34K | 2.0M |
| 2026-10-23 | SCHACHLE JOSEPH K | Chief Operating Officer | Sell | 5K | $3.56 | $17K | 287K |
| 2026-10-23 | Gagnon Robert E. | Chief Financial Officer | Sell | 14K | $3.55 | $50K | 542K |
| 2026-09-30 | Foundation Fighting Blindness Retinal Degeneration Fund | Director, See Remarks | Sell | 556K | $4.96 | $2.8M | 3.2M |
| 2026-09-09 | Magrath George | Chief Executive Officer | Tax withholding | 76K | $5.97 | $451K | 2.0M |
| 2026-09-09 | Magrath George | Chief Executive Officer | Exercise or conversion | 392K | $1.15 | $451K | 2.1M |
| 2026-09-08 | Gallagher Cam | Director | Exercise or conversion | 784K | $1.15 | $902K | 2.8M |
| 2026-09-03 | Gagnon Robert E. | Chief Financial Officer | Sell | 28K | $4.54 | $127K | 556K |
| 2026-07-23 | YERXA BENJAMIN R | President | Sell | 7K | $2.97 | $22K | 704K |
| 2026-07-23 | SCHACHLE JOSEPH K | Chief Operating Officer | Sell | 5K | $2.94 | $14K | 291K |
| 2026-07-23 | Magrath George | Chief Executive Officer | Sell | 9K | $2.95 | $28K | 1.7M |
| 2026-07-23 | Gagnon Robert E. | Chief Financial Officer | Sell | 8K | $2.95 | $23K | 584K |
| 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund | Director, See Remarks | Sell | 1.7M | $4.35 | $7.4M | 3.8M |
| 2026-04-23 | YERXA BENJAMIN R | President | Sell | 7K | $5.24 | $39K | 712K |
| 2026-04-23 | SCHACHLE JOSEPH K | Chief Operating Officer | Sell | 5K | $5.22 | $25K | 296K |
| 2026-04-23 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Sell | 2K | $5.20 | $9K | 189K |
| 2026-04-23 | Magrath George | Chief Executive Officer | Sell | 10K | $5.22 | $50K | 1.7M |
| 2026-04-23 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Sell | 8K | $5.19 | $39K | 509K |
| 2026-04-23 | Gagnon Robert E. | Chief Financial Officer | Sell | 8K | $5.18 | $41K | 592K |
| 2026-04-20 | Rodgers Richard J | Director | Grant | 24K | $0.00 | $0 | 343K |
| 2026-04-20 | MANUSO JAMES S J | Director | Grant | 24K | $0.00 | $0 | 317K |
| 2026-04-20 | Graves Adrienne L | Director | Grant | 24K | $0.00 | $0 | 128K |
| 2026-04-20 | Gallagher Cam | Director | Grant | 24K | $0.00 | $0 | 2.0M |
| 2026-04-20 | Benton Susan | Director | Grant | 24K | $0.00 | $0 | 244K |
| 2026-04-20 | Bennett Jean | Director | Grant | 24K | $0.00 | $0 | 259K |
| 2026-04-20 | Ainsworth Sean | Director | Grant | 24K | $0.00 | $0 | 322K |
| 2026-03-16 | SCHACHLE JOSEPH K | Chief Operating Officer | Sell | 4K | $5.25 | $20K | 301K |
| 2026-03-16 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Sell | 3K | $5.25 | $15K | 190K |
| 2026-03-16 | Magrath George | Chief Executive Officer | Sell | 24K | $5.21 | $127K | 1.8M |
| 2026-03-16 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Sell | 4K | $5.12 | $19K | 517K |
| 2026-02-12 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Tax withholding | 5K | $3.39 | $18K | 520K |
| 2026-01-22 | YERXA BENJAMIN R | President | Grant | 400K | $0.00 | $0 | 719K |
| 2026-01-22 | SCHACHLE JOSEPH K | Chief Operating Officer | Grant | 250K | $0.00 | $0 | 305K |
| 2026-01-22 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Grant | 87K | $0.00 | $0 | 193K |
| 2026-01-22 | Magrath George | Chief Executive Officer | Grant | 484K | $0.00 | $0 | 1.8M |
| 2026-01-22 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Grant | 400K | $0.00 | $0 | 526K |
| 2026-01-22 | Gagnon Robert E. | Chief Financial Officer | Grant | 400K | $0.00 | $0 | 600K |
| 2026-01-18 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Tax withholding | 3K | $2.10 | $7K | 107K |
| 2026-01-10 | Zaremba Rabourn Amy | Head of Fin. Quality Assurance | Tax withholding | 4K | $1.93 | $8K | 110K |
| 2026-01-06 | Gallagher Cam | Director | Grant | 67K | $0.00 | $0 | 2.0M |
| 2026-01-01 | Ainsworth Sean | Director | Grant | 43K | price not stated in the filing | not stated | 297K |
| 2026-01-01 | Bennett Jean | Director | Grant | 21K | price not stated in the filing | not stated | 235K |
| 2026-01-01 | Graves Adrienne L | Director | Grant | 24K | price not stated in the filing | not stated | 103K |
| 2026-01-01 | MANUSO JAMES S J | Director | Grant | 31K | price not stated in the filing | not stated | 293K |
| 2025-12-31 | Gallagher Cam | Director | Grant | 33K | $0.00 | $0 | 1.9M |
| 2025-12-29 | Gallagher Cam | Director | Buy | 83K | $1.97 | $163K | 83K |
| 2025-12-29 | Gallagher Cam | Director | Buy | 81K | $1.98 | $160K | 1.9M |
| 2025-12-09 | Foundation Fighting Blindness Retinal Degeneration Fund | Director, See Remarks | Sell | 4.0M | $2.15 | $8.6M | 5.5M |
| 2025-11-01 | Magrath George | Chief Executive Officer | Tax withholding | 30K | $2.30 | $70K | 1.3M |
| 2025-10-22 | YERXA BENJAMIN R | President | Tax withholding | 24K | $1.95 | $46K | 319K |
| 2025-09-10 | Gagnon Robert E. | Chief Financial Officer | Grant | 200K | $0.00 | $0 | 200K |
| 2025-08-25 | Gallagher Cam | Director | Grant | 870K | $1.15 | $1000K | 1.8M |
| 2025-08-25 | Ainsworth Sean | Director | Grant | 87K | $1.15 | $100K | 255K |
| 2025-05-05 | Foundation Fighting Blindness, Inc. | Director,TenPercentOwner,Other | Conversion | 6.9M | price not stated in the filing | not stated | 9.5M |
| 2025-04-30 | Ainsworth Sean | Director | Grant | 80K | $0.00 | $0 | 168K |
| 2025-04-30 | Bennett Jean | Director | Grant | 80K | $0.00 | $0 | 214K |
| 2025-04-30 | Benton Susan | Director | Grant | 80K | $0.00 | $0 | 220K |
| 2025-04-30 | Gallagher Cam | Director | Grant | 80K | $0.00 | $0 | 941K |
| 2025-04-30 | Graves Adrienne L | Director | Grant | 80K | $0.00 | $0 | 80K |
| 2025-04-30 | MANUSO JAMES S J | Director | Grant | 80K | $0.00 | $0 | 262K |
| 2025-04-30 | Rodgers Richard J | Director | Grant | 80K | $0.00 | $0 | 319K |
| 2025-03-24 | Gallagher Cam | Director | Grant | 784K | price not stated in the filing | not stated | 861K |
| 2025-03-24 | Magrath George | Chief Executive Officer | Grant | 392K | price not stated in the filing | not stated | 1.3M |
| 2025-03-13 | Hoffmann Bernhard | SVP of Corp. Dev. | Grant | 30K | $0.00 | $0 | 185K |
| 2025-03-13 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Grant | 53K | $0.00 | $0 | 126K |
| 2025-03-13 | Jhaveri Nirav S. | Chief Financial Officer | Grant | 53K | $0.00 | $0 | 194K |
| 2025-03-13 | Magrath George | Chief Executive Officer | Grant | 331K | $0.00 | $0 | 930K |
| 2025-03-13 | Zaremba Rabourn Amy | SVP of Finance | Grant | 40K | $0.00 | $0 | 114K |
| 2025-03-13 | SCHACHLE JOSEPH K | Chief Operating Officer | Grant | 53K | $0.00 | $0 | 55K |
| 2025-02-13 | Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | Tax withholding | 5K | $1.15 | $6K | 73K |
| 2025-02-13 | Jhaveri Nirav S. | Chief Financial Officer | Tax withholding | 8K | $1.15 | $9K | 142K |
| 2025-02-04 | Hoffmann Bernhard | SVP of Corp. Dev. | Tax withholding | 7K | $1.14 | $8K | 156K |
| 2025-02-04 | Zaremba Rabourn Amy | SVP of Finance | Tax withholding | 8K | $1.14 | $9K | 74K |
| 2025-01-02 | Bennett Jean | Director | Grant | 34K | price not stated in the filing | not stated | 134K |
| 2025-01-02 | MANUSO JAMES S J | Director | Grant | 50K | price not stated in the filing | not stated | 182K |
| 2024-12-26 | Magrath George | Chief Executive Officer | Buy | 100K | $0.98 | $98K | 599K |
| 2024-12-23 | Magrath George | Chief Executive Officer | Grant | 6K | $0.00 | $0 | 499K |
| 2024-11-21 | YERXA BENJAMIN R | President | Buy | 10K | $0.98 | $10K | 343K |
| 2024-11-18 | Magrath George | Chief Executive Officer | Buy | 10K | $1.02 | $10K | 493K |
| 2024-11-15 | Magrath George | Chief Executive Officer | Buy | 90K | $1.01 | $91K | 483K |
| 2024-11-07 | YERXA BENJAMIN R | President | Grant | 333K | $0.00 | $0 | 333K |
| 2024-11-01 | Magrath George | Chief Executive Officer | Tax withholding | 37K | $1.18 | $44K | 393K |
| 2024-10-22 | Bennett Jean | Director | Grant | 100K | $0.00 | $0 | 100K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON14 Form 144 notices on file for IRD worth $819K at the prices reported; 4 in the last 90 days worth $332K. Latest: YERXA BENJAMIN R filed on 2026-10-23 to sell 33,189 shares ($117K) from 2026-10-23.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-23 | YERXA BENJAMIN ROfficer | 33K | $117K | 0.040% | 2026-10-23 | Raymond James & Associates, Inc. |
| 2026-10-23 | Gagnon Robert E.Officer | 14K | $56K | 0.017% | 2026-10-23 | Jefferies LLC |
| 2026-10-23 | Magrath GeorgeOfficer | 10K | $34K | 0.012% | 2026-10-23 | Raymond James & Associates, Inc. |
| 2026-09-03 | Gagnon Robert E.Officer | 28K | $125K | 0.034% | 2026-09-03 | Jefferies LLC |
| 2026-07-23 | SCHACHLE JOSEPH KOfficer | 5K | $14K | 0.006% | 2026-07-23 | Raymond James & Associates |
| 2026-07-23 | YERXA BENJAMIN ROfficer | 7K | $22K | 0.009% | 2026-07-23 | Raymond James & Associates |
| 2026-07-23 | Magrath GeorgeOfficer | 9K | $29K | 0.011% | 2026-07-23 | Jefferies LLC |
| 2026-07-23 | Gagnon Robert E.Officer | 8K | $24K | 0.009% | 2026-07-23 | Jefferies LLC |
| 2026-04-23 | SCHACHLE JOSEPH KOfficer | 5K | $25K | 0.007% | 2026-04-23 | Raymond James & Associates |
| 2026-04-23 | YERXA BENJAMIN ROfficer | 7K | $39K | 0.010% | 2026-04-23 | Raymond James & Associates |
| 2026-04-23 | Magrath GeorgeOfficer | 10K | $127K | 0.013% | 2026-04-23 | Raymond James & Associates |
| 2026-04-23 | Jayagopal AshwathOfficer | 8K | $39K | 0.011% | 2026-04-23 | Raymond James & Associates |
| 2026-04-23 | Gagnon Robert E.Officer | 8K | $41K | 0.011% | 2026-04-23 | Raymond James & Associates |
| 2026-03-16 | Magrath GeorgeOfficer | 24K | $127K | 0.035% | 2026-03-16 | Raymond James & Associates |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON17 holders report 5% or more of IRD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Joseph Edelman at 10.0% of the class (9,233,710 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G | BlackRock, Inc.parent holding company | 5.0M | 6.1% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 1 | Caligan Partners LPinvestment adviser, partnership | 6.1M | 7.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | JOHNSON DAVID EDWARDparent holding company, individual | 6.1M | 7.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Joseph Edelmanindividual | 9.2M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Perceptive Advisors LLCinvestment adviser | 9.2M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Perceptive Life Sciences Master Fund, Ltd.corporation | 9.2M | 10.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dames GP LLCparent holding company, other entity | 5.5M | 6.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Dmitry Balyasnyparent holding company, individual | 5.5M | 6.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BALYASNY ASSET MANAGEMENT L.P.investment adviser, partnership | 5.5M | 6.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | BAM GP LLCparent holding company, other entity | 5.5M | 6.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Balyasny Asset Management Holdings LPparent holding company, partnership | 5.5M | 6.6% | 2026-06-30 |
| 2026-05-20 | 13D/Ano. 3 | Foundation Fighting Blindness Retinal Degeneration Fundcorporation, other entity | 3.8M | 4.7% | 2026-05-18 |
| 2026-05-20 | 13D/Ano. 3 | Foundation Fighting Blindness, Inc.corporation | 3.8M | 4.7% | 2026-05-18 |
| 2026-05-15 | 13G/Ano. 3 | Nantahala Capital Management, LLCinvestment adviser | 4.8M | 6.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Wilmot B. Harkeyparent holding company | 4.8M | 6.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Daniel Mackparent holding company | 4.8M | 6.5% | 2026-03-31 |
| 2026-05-13 | 13G/Ano. 2 | CAVU ADVISORS, LLCpartnership | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | LESLIE W. KREISindividual | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | AARON G.L. FLETCHERindividual | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | CAVU MANAGEMENT, LPpartnership | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | BIOS EQUITY PARTNERS III, LPpartnership | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | BIOS CAPITAL MANAGEMENT, LPpartnership | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | BIOS ADVISORS GP, LLCpartnership | 3.7M | 4.5% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | BIOS FUND III QP, LPpartnership | 2.8M | 3.4% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | BIOS FUND III NT, LPpartnership | 451K | 0.6% | 2026-05-12 |
| 2026-05-13 | 13G/Ano. 2 | BIOS FUND III, LPpartnership | 431K | 0.5% | 2026-05-12 |
| 2026-05-13 | 13G | Adage Capital Management, L.P.investment adviser, partnership | 6.0M | 8.5% | 2026-03-31 |
| 2026-05-13 | 13G | Phillip Grossparent holding company, individual | 6.0M | 8.5% | 2026-03-31 |
| 2026-05-13 | 13G | Robert Atchinsonparent holding company, individual | 6.0M | 8.5% | 2026-03-31 |
13F holders
Tracked managers holding IRD at their latest 13F. JSON4 of the 30 tracked managers held IRD at their latest 13F, $13.3M in total at quarter-end prices. Millennium Management is the largest at $9.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 2.3M | $9.5M | 0.00% | -328K |
| Citadel Advisors | 2026-06-30 | 666K | $2.7M | 0.00% | +545K |
| Two Sigma Investments | 2026-06-30 | 254K | $1.0M | 0.00% | +145K |
| Point72 Asset Management | 2026-06-30 | 19K | $78K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Opus Genetics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Opus Genetics (IRD), SEC CIK 1228627, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-23.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-23.JSON and CSV
- Company record
- EDGAR filing index for CIK 1228627Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of IRD is sold short?
13,337,904 shares were held short at the 2026-10-15 settlement, 7.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is IRD's daily short volume?
On 2026-11-02, 231,048 of the 355,597 IRD shares reported to FINRA were sold short, 65.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does IRD have fails to deliver?
The SEC's latest file shows 99 IRD shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are IRD insiders buying or selling?
Insiders at IRD reported 7 open-market sells worth $3.1M in the last 90 days and no open-market buys. Latest filing: YERXA BENJAMIN R (President) on 2026-10-23.
Have IRD insiders filed to sell?
14 Form 144 notices on file for IRD worth $819K at the prices reported; 4 in the last 90 days worth $332K. Latest: YERXA BENJAMIN R filed on 2026-10-23 to sell 33,189 shares ($117K) from 2026-10-23.
Who owns 5% or more of IRD?
17 holders report 5% or more of IRD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Joseph Edelman at 10.0% of the class (9,233,710 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own IRD?
4 of the 30 tracked 13F managers held IRD shares at their latest filing, $13.3M in all. The largest: Izzy Englander's Millennium Management (2.3M shares, $9.5M), Ken Griffin's Citadel Advisors (666K shares, $2.7M), Two Sigma Investments (254K shares, $1.0M), Steve Cohen's Point72 Asset Management (19K shares, $78K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.